Benzazepine dicarboxamide compounds

Patent metadata

Field	Value
Publication number	US-9597333-B2
Application number	US-201615279114-A
Country	US
Kind code	B2
Filing date	Sep 28, 2016
Priority date	Mar 6, 2015
Publication date	Mar 21, 2017
Grant date	Mar 21, 2017

Abstract

This invention relates to novel benzazepine dicarboxamide compounds of the formula

wherein R 1 to R 4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

First claim

The invention claimed is:

1. A method of activating TLR-8 receptor in a subject in need thereof, wherein said subject is suffering from a disease or disorder selected the group consisting of cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious disease, the method comprising administering to said subject an effective amount of a compound of formula I

wherein
R 1 is C 3-7 -alkyl or C 3-7 -cycloalkyl;
R 2 is selected from the group consisting of C 1-7 -alkyl, hydroxy-C 1-7 -alkyl, C 2-7 -alkenyl, C 3-7 -alkinyl, amino-C 1-7 -alkoxy-C 1-7 -alkyl, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, halogen-C 1-7 -alkyl, C 3-7 -cycloalkyl-C 1-7 -alkyl and phenyl-C 1-7 -alkyl, wherein phenyl is unsubstituted or substituted by amino-C 1-7 -alkyl;
R 3 is hydrogen;
R 4 is selected from the group consisting of
phenyl, said phenyl being unsubstituted or substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, hydroxy-C 1-7 -alkyl, amino-C 1-7 -alkyl, C 1-7 -alkyl-amino-C 1-7 -alkyl, di-C 1-7 -alkyl-amino-C 1-7 -alkyl, amino-C 2-7 -alkenyl, C 1-7 -alkyl-amino-C 2-7 -alkenyl, di-C 1-7 -alkyl-amino-C 2-7 -alkenyl, amino-C 2-7 -alkinyl, C 1-7 -alkyl-amino-C 2-7 -alkinyl, di-C 1-7 -alkyl-amino-C 2-7 -alkinyl, benzyloxycarbonylamino-C 1-7 -alkyl, amino-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkyl, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, C 1-7 -alkylsulfonyl, heterocyclylcarbonyl and phenyl-C 1-7 -alkyl, wherein phenyl is unsubstituted or substituted by C 1-7 -alkoxy or amino-C 1-7 -alkyl, and
heteroaryl, said heteroaryl being a 5- or 6-membered aromatic ring containing one, two or three heteroatoms selected from N, O or S and being unsubstituted or substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, hydroxy-C 1-7 -alkyl, amino-C 1-7 -alkyl, C 1-7 -alkyl-amino-C 1-7 -alkyl, di-C 1-7 -alkyl-amino-C 1-7 -alkyl, amino-C 2-7 -alkenyl, C 1-7 -alkyl-amino-C 2-7 -alkenyl, di-C 1-7 -alkyl-amino-C 2-7 -alkenyl, amino-C 2-7 -alkinyl, C 1-7 -alkyl-amino-C 2-7 -alkinyl, di-C 1-7 -alkyl-amino-C 2-7 -alkinyl, benzyloxycarbonylamino-C 1-7 -alkyl, amino-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkyl, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, C 1-7 -alkylsulfonyl, heterocyclylcarbonyl and phenyl-C 1-7 -alkyl, wherein phenyl is unsubstituted or substituted by C 1-7 -alkoxy or amino-C 1-7 -alkyl,

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein R 1 is C 1-7 -alkyl.

3. The method of claim 1 wherein R 1 is propyl or butyl.

4. The method of claim 1 wherein R 2 is selected from the group consisting of C 1-7 -alkyl, C 3-7 -alkinyl, halogen-C 1-7 -alkyl, C 3-7 -cycloalkyl-C 1-7 -alkyl and hydroxy-C 1-7 -alkyl.

5. The method of claim 1 wherein R 2 is C 1-7 -alkyl.

6. The method of claim 1 wherein R 4 is a 5- or 6-membered heteroaryl ring containing one, two or three heteroatoms selected from N, O or S and being unsubstituted or substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, hydroxy-C 1-7 -alkyl, amino-C 1-7 -alkyl, C 1-7 -alkyl-amino-C 1-7 -alkyl, di-C 1-7 -alkyl-amino-C 1-7 -alkyl, amino-C 2-7 -alkenyl, C 1-7 -alkyl-amino-C 2-7 -alkenyl, di-C 1-7 -alkyl-amino-C 2-7 -alkenyl, amino-C 2-7 -alkinyl, C 1-7 -alkyl-amino-C 2-7 -alkinyl, di-C 1-7 -alkyl-amino-C 2-7 -alkinyl, benzyloxycarbonylamino-C 1-7 -alkyl, amino-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkyl, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, C 1-7 -alkylsulfonyl, heterocyclylcarbonyl and phenyl-C 1-7 -alkyl, wherein phenyl is unsubstituted or substituted by C 1-7 -alkoxy or amino-C 1-7 -alkyl.

7. The method of claim 1 wherein R 4 is a 5- or 6-membered heteroaryl ring containing one, two or three heteroatoms selected from N, O or S and being substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, C 1-7 -alkoxy, hydroxy-C 1-7 -alkyl, amino-C 1-7 -alkyl, di-C 1-7 -alkyl-amino-C 1-7 -alkyl, amino-C 2-7 -alkenyl, amino-C 2-7 -alkinyl, benzyloxycarbonylamino-C 1-7 -alkyl, amino-C 1-7 -alkoxy and phenyl-C 1-7 -alkyl, wherein phenyl is unsubstituted or substituted by C 1-7 -alkoxy or amino-C 1-7 -alkyl.

8. The method of claim 1 wherein R 4 is a 5- or 6-membered heteroaryl ring is selected from the group consisting of imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl and pyrimidinyl.

9. The method of claim 1 wherein the 6-membered heteroaryl ring is pyridyl.

10. The method of claim 1 wherein R 4 is phenyl, said phenyl being unsubstituted or substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, hydroxy-C 1-7 -alkyl, amino-C 1-7 -alkyl, amino-C 1-7 -alkyl, C 1-7 -alkyl-amino-C 1-7 -alkyl, di-C 1-7 -alkyl-amino-C 1-7 -alkyl, amino-C 2-7 -alkenyl, C 1-7 -alkyl-amino-C 2-7 -alkenyl, di-C 1-7 -alkyl-amino-C 2-7 -alkenyl, amino-C 2-7 -alkinyl, C 1-7 -alkyl-amino-C 2-7 -alkinyl, di-C 1-7 -alkyl-amino-C 2-7 -alkinyl, benzyloxycarbonylamino-C 1-7 -alkyl, amino-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkyl, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, C 1-7 -alkylsulfonyl, heterocyclylcarbonyl and phenyl-C 1-7 -alkyl, wherein phenyl is unsubstituted or substituted by C 1-7 -alkoxy or amino-C 1-7 -alkyl.

11. The method of claim 1 wherein R 4 is phenyl, said phenyl being unsubstituted or substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, amino-C 1-7 -alkyl, amino-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkyl, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, C 1-7 -alkylsulfonyl and heterocyclylcarbonyl.

12. The method of claim 1 wherein R 4 is phenyl substituted by one group selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, amino-C 1-7 -alkyl, amino-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkyl, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, C 1-7 -alkylsulfonyl and heterocyclylcarbonyl.

13. The method of claim 1 wherein
R 1 is C 3-7 -alkyl or C 3-7 -cycloalkyl;
R 2 is selected from the group consisting of C 1-7 -alkyl, C 2-7 -alkenyl, C 3-7 -alkinyl, hydroxy-C 1-7 -alkyl, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, halogen-C 1-7 -alkyl and C 3-7 -cycloalkyl-C 1-7 -alkyl;
R 3 is hydrogen;
R 4 is selected from the group consisting of
phenyl, said phenyl being unsubstituted or substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, hydroxy-C 1-7 -alkyl, amino-C 1-7 -alkyl, amino-C 2-7 -alkenyl, amino-C 2-7 -alkinyl, amino-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkoxy, amino-C 1-7 -alkoxy-C 1-7 -alkoxy-C 1-7 -alkyl, C 1-7 -alkylsulfonyl and heterocyclylcarbonyl, and
heteroaryl, said heteroaryl being a 5- or 6-membered aromatic ring containing one, two or three heteroatoms selected from N, O or S and being unsubstituted or substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, hydroxy-C 1-7 -alkyl, amino-C 1-7 -alkyl, amino-C 2-7

Assignees

• Hoffmann La Roche

Inventors

• Hoves Sabine
• Wang Lisha
• Yun Hongying
• Zhang Weixing
• Zhu Wei

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P35/04

  specific for metastasis · CPC title